Top entities: PeproMene Bio, PMB-CT01, Larry W. Kwak, European Hematology Association.

What category does this event fall under?

Tech — classified as medical breakthrough.

What is the sentiment of coverage?

Aggregate sentiment score: 70 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Tech medical breakthrough

PeproMene Bio PMB-CT01 Lymphoma Results

Q: When did this event occur?

First reported May 28, 2026; last updated May 28, 2026.

Q: What is the market impact?

General. The positive clinical data for PMB-CT01 from PeproMene Bio could significantly impact the biotechnology and pharmaceutical markets by introducing a new, effective treatment for B-cell lymphomas, especially for patients who have failed prior therapies.

Analysis based on 7 articles · First reported May 28, 2026 · Last updated May 28, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The positive clinical data for PMB-CT01 from PeproMene Bio could significantly impact the biotechnology and pharmaceutical markets by introducing a new, effective treatment for B-cell lymphomas, especially for patients who have failed prior therapies. This success could lead to increased investor interest in PeproMene Bio and similar CAR T-cell therapies, potentially driving up valuations in the sector.

Biotechnology Pharmaceuticals Healthcare

Event Summary

PeproMene Bio announced updated clinical data from its Phase 1 study of PMB-CT01, a BAFF-R-targeted CAR T-cell therapy, at the 2026 Congress of the European Hematology Association. The study, focusing on relapsed/refractory B-cell non-Hodgkin lymphoma patients, including those who failed prior CD19 CAR T-cell therapy, showed a promising safety profile with no dose-limiting toxicities or severe cytokine release syndrome/neurotoxicity. Importantly, PMB-CT01 achieved a 78% complete response rate among nine patients, with durable responses lasting over 3 years and all responding patients achieving minimal residual disease-negative status. Larry W. Kwak, scientific founder of PeproMene Bio, highlighted the validation of BAFF-R as a novel target and the potential for outpatient use due to the favorable safety. The trial is expanding to include more patients with mantle cell lymphoma, large B-cell lymphoma, and follicular lymphoma.

Entities Involved

priv

PeproMene Bio

As the developer of PMB-CT01, PeproMene Bio is the central entity in this event, benefiting from positive clinical trial results that validate its therapeutic approach and potentially increase its market value and future commercialization prospects.

Importance 100.0 Sentiment 75.0

oth

PMB-CT01

PMB-CT01 is the investigational CAR T-cell therapy showing promising safety and durable responses in B-cell lymphomas, making it a key asset for PeproMene Bio and a potential new treatment option for patients.

Importance 90.0 Sentiment 70.0

per

Larry W. Kwak

As the scientific founder and presenter, Larry W. Kwak's reputation is enhanced by the positive clinical trial results of PMB-CT01, validating his research and contributions to the field.

Importance 80.0 Sentiment 60.0

ngo

European Hematology Association

The European Hematology Association is hosting the presentation of the clinical data, providing a platform for PeproMene Bio to disseminate its findings.

Importance 20.0 Sentiment 10.0

ERGEN INTELLIGENCE

Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard